Health
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expande
About this update from Neuronetics, Inc.
[{"type":"image","alt":"Neuronetics","displaySize":"","headline":null,"caption":"Neuronetics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/c9ec2695435007e9fe00ba41ba1a5be2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/scHOldrogkGah0UUhyJ.bA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c9ec2695435007e9fe00ba41ba1a5be2","width":300,"height":74}},"lazy":false},{"type":"text","content":"Policy update increases access for millions covered by Evernorth Health Services","length":80,"tagName":"p"},{"type":"text","content":"MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older living with major depressive disorder (MDD). As these health policies cover 15 million lives, the expansion greatly improves access to non-drug treatment options for adolescent patients who are seeking non-drug options for depression.","length":769,"tagName":"p"},{"type":"text","content":"The expansion is effective immediately, nearly one year after NeuroStar® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the past year, several leading insurers have rapidly updated their policies to reflect the FDA clearance, including but not limited to Humana, Aetna, Medi-Cal, BCBS-HCSC, Pacific Source, and more.","length":390,"tagName":"p"},{"type":"text","content":"“This decision by Cigna/Evernorth is a significant step forward for adolescent mental healthcare and reflects the momentum we have built with payors over the past year since NeuroStar first received the FDA clearance for adolescents,” said Keith J. Sullivan, President and CEO of Neuronetics. “We are grateful that millions more families will now have easier access to NeuroStar TMS as a proven, non-drug treatment for major depression and can get the ...